Belvedere Trading’s VanEck Biotech ETF BBH Stock Holding History

Belvedere Trading’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$305K	Buy	1,500 +1,000	+200%	+$188K	﹤0.01%	446
2026 Q1	$94K	Buy	+500	New	+$96.3K	﹤0.01%	521
2025 Q4	–	Sell	-1,800	Closed	-$298K	–	877
2025 Q3	$298K	Hold	1,800	–	–	﹤0.01%	385
2025 Q2	$276K	Buy	+1,800	New	+$268K	﹤0.01%	355

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Belvedere Trading's BBH Position: Q2 2026 in Review

Belvedere Trading increased its VanEck Biotech ETF (BBH) stake by 83% in Q2 2026, buying an estimated $95.2K and bringing the position to 1,112 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #543.

Belvedere Trading first reported a position in BBH in Q1 2026 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

Belvedere Trading held 1,112 shares of VanEck Biotech ETF worth $226K as of Q2 2026.
Belvedere Trading bought 506 VanEck Biotech ETF shares in Q2 2026, an estimated $95.2K.
VanEck Biotech ETF made up ﹤0.01% of Belvedere Trading's portfolio in Q2 2026, its #543 holding.
Belvedere Trading first reported a position in VanEck Biotech ETF in Q1 2026 and has held it in 2 quarters since.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Belvedere Trading's 13F filing for Q2 2026, filed 31 Jul 2026.